Literature DB >> 7768965

Differential expression of TIS21 and TIS1 genes in the various organs of Balb/c mice, thymic carcinoma tissues and human cancer cell lines.

I K Lim1, M S Lee, S H Lee, N K Kim, I Jou, J S Seo, S C Park.   

Abstract

As a part of a series of investigations on the functions of TIS21 and TIS1 genes, we measured in vivo 12-O-tetradecanoylphorbol-13-acetate (TPA) inducibility of primary response genes (TIS21, TIS8 and TIS1) in the Balb/c mice and the changes of TIS gene expression in thymic carcinoma tissues and A549 and NCIH69 human lung cancer cell lines. In vivo induction of the TIS genes (TIS21, -8 and -1) by intraperitoneal injection of TPA was dramatic only at the needle contact site, i.e. in the abdominal muscle, not in the thigh muscle. Expression of TIS21 and TIS1 in the Balb/c mice thymus, lung, stomach and spleen was very strong (Lim IK et al. 1994a), regardless of TPA injection. Thymic carcinoma tissues developed in SV40-T-antigen-containing transgenic mice did not express TIS21 and TIS1, and expressed TIS8 weakly. Interestingly, induction of TIS21 expression was obliterated in the human lung cancer cells; A549 cells completely lost the ability to express TIS21 after a combined treatment of TPA and cycloheximide. We also measured the induction of TIS genes by TPA and/or cycloheximide in Raw264.7 mouse macrophage cells and U937 human histiocytic lymphoma cells. However, the induction profile was quite different; repressed and deregulated expression in the U937 cells as compared to rapid and transient induction of TIS genes in the Raw264.7 cells. These data may suggest a repressed expression of TIS21 and TIS1 in the cancer tissues and cells derived from the organs that constitutively express TIS21 in mice and in human cancer cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768965     DOI: 10.1007/BF01209594

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  24 in total

1.  Structure and expression of TIS21, a primary response gene induced by growth factors and tumor promoters.

Authors:  B S Fletcher; R W Lim; B C Varnum; D A Kujubu; R A Koski; H R Herschman
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

Review 2.  Primary response genes induced by growth factors and tumor promoters.

Authors:  H R Herschman
Journal:  Annu Rev Biochem       Date:  1991       Impact factor: 23.643

3.  A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor.

Authors:  J Milbrandt
Journal:  Science       Date:  1987-11-06       Impact factor: 47.728

4.  A gene coding for a zinc finger protein is induced during 12-O-tetradecanoylphorbol-13-acetate-stimulated HL-60 cell differentiation.

Authors:  N Shimizu; M Ohta; C Fujiwara; J Sagara; N Mochizuki; T Oda; H Utiyama
Journal:  J Biochem       Date:  1992-02       Impact factor: 3.387

5.  TIS gene expression in cultured rat astrocytes: induction by mitogens and stellation agents.

Authors:  A T Arenander; R W Lim; B C Varnum; R Cole; J de Vellis; H R Herschman
Journal:  J Neurosci Res       Date:  1989-07       Impact factor: 4.164

6.  Sequence analysis reveals that the BTG1 anti-proliferative gene is conserved throughout evolution in its coding and 3' non-coding regions.

Authors:  J P Rouault; C Samarut; L Duret; C Tessa; J Samarut; J P Magaud
Journal:  Gene       Date:  1993-07-30       Impact factor: 3.688

7.  Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the immediate-early gene nur77.

Authors:  Z G Liu; S W Smith; K A McLaughlin; L M Schwartz; B A Osborne
Journal:  Nature       Date:  1994-01-20       Impact factor: 49.962

8.  Preferential primary-response gene expression in promotion-resistant versus promotion-sensitive JB6 cells.

Authors:  J L Cmarik; H Herschman; N H Colburn
Journal:  Mol Carcinog       Date:  1994-10       Impact factor: 4.784

9.  BTG1, a member of a new family of antiproliferative genes.

Authors:  J P Rouault; R Rimokh; C Tessa; G Paranhos; M Ffrench; L Duret; M Garoccio; D Germain; J Samarut; J P Magaud
Journal:  EMBO J       Date:  1992-04       Impact factor: 11.598

10.  Structure, mapping and expression of a growth factor inducible gene encoding a putative nuclear hormonal binding receptor.

Authors:  R P Ryseck; H Macdonald-Bravo; M G Mattéi; S Ruppert; R Bravo
Journal:  EMBO J       Date:  1989-11       Impact factor: 11.598

View more
  15 in total

1.  TIS21/BTG2 inhibits breast cancer growth and progression by differential regulation of mTORc1 and mTORc2-AKT1-NFAT1-PHLPP2 signaling axis.

Authors:  Santhoshkumar Sundaramoorthy; Preethi Devanand; Min Sook Ryu; Kye Yong Song; Dong Young Noh; In Kyoung Lim
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-28       Impact factor: 4.553

2.  TIS21/BTG2 inhibits invadopodia formation by downregulating reactive oxygen species level in MDA-MB-231 cells.

Authors:  Jung-A Choi; In Kyoung Lim
Journal:  J Cancer Res Clin Oncol       Date:  2013-08-02       Impact factor: 4.553

Review 3.  TIS21 (/BTG2/PC3) as a link between ageing and cancer: cell cycle regulator and endogenous cell death molecule.

Authors:  In Kyoung Lim
Journal:  J Cancer Res Clin Oncol       Date:  2006-02-03       Impact factor: 4.553

4.  Inhibition of breast cancer invasion by TIS21/BTG2/Pc3-Akt1-Sp1-Nox4 pathway targeting actin nucleators, mDia genes.

Authors:  J-A Choi; Y S Jung; J Y Kim; H M Kim; I K Lim
Journal:  Oncogene       Date:  2015-03-23       Impact factor: 9.867

5.  Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray.

Authors:  Elin Möllerström; Anikó Kovács; Kristina Lövgren; Szilard Nemes; Ulla Delle; Anna Danielsson; Toshima Parris; Donal J Brennan; Karin Jirström; Per Karlsson; Khalil Helou
Journal:  BMC Cancer       Date:  2010-06-16       Impact factor: 4.430

6.  How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update.

Authors:  Alberto Vogrig; Sergio Muñiz-Castrillo; Antonio Farina; Jérôme Honnorat; Bastien Joubert
Journal:  J Neurol       Date:  2021-10-27       Impact factor: 4.849

7.  B cell translocation gene 2 enhances susceptibility of HeLa cells to doxorubicin-induced oxidative damage.

Authors:  Young-Bin Lim; Tae Jun Park; In Kyoung Lim
Journal:  J Biol Chem       Date:  2008-10-07       Impact factor: 5.157

8.  BTG2 suppresses cancer cell migration through inhibition of Src-FAK signaling by downregulation of reactive oxygen species generation in mitochondria.

Authors:  Seo-Kyung Lim; Yong Won Choi; In Kyoung Lim; Tae Jun Park
Journal:  Clin Exp Metastasis       Date:  2012-05-06       Impact factor: 5.150

9.  Impact of BTG2 expression on proliferation and invasion of gastric cancer cells in vitro.

Authors:  Lin Zhang; Haili Huang; Kai Wu; Mengwei Wang; Benyan Wu
Journal:  Mol Biol Rep       Date:  2009-09-02       Impact factor: 2.316

10.  Crystal structures of human BTG2 and mouse TIS21 involved in suppression of CAF1 deadenylase activity.

Authors:  Xiuna Yang; Masahiro Morita; Hui Wang; Toru Suzuki; Wen Yang; Yunhai Luo; Cong Zhao; Yue Yu; Mark Bartlam; Tadashi Yamamoto; Zihe Rao
Journal:  Nucleic Acids Res       Date:  2008-10-30       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.